Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments.
Fatigue
Fatigue Severity Impact Questionnaire—Relapsing Multiple Sclerosis (FSIQ-RMS)
Patient-reported outcome (PRO)
Primary and secondary progressive multiple sclerosis (PPMS and SPMS)
Progressive multiple sclerosis (progressive MS)
Qualitative patient interview study
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
17
12
2021
accepted:
14
02
2022
pubmed:
11
3
2022
medline:
11
3
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS) but is challenging to assess and has not been comprehensively characterized in patients with progressive MS. This study aimed to (1) obtain qualitative evidence from patients with progressive MS to characterize MS-related fatigue concepts and their impacts on health-related quality of life (HRQoL), and (2) evaluate the conceptual frameworks of existing MS-specific fatigue patient-reported outcome (PRO) instruments using study data to determine the most suitable PRO instrument in this population. Qualitative interviews were conducted with 30 US participants with confirmed progressive MS and fatigue in the last 6 months to assess their MS-related fatigue. Data were compared with concepts in existing PRO instruments to evaluate their relevance in progressive MS. Physical and mental concepts of fatigue were identified and characterized distinctly from patients with progressive MS. Most patients characterized fatigue as occurring daily and lasting several hours, with negative impacts on HRQoL. Concept mapping to existing MS-specific fatigue PRO instruments supported the Fatigue Severity Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) as the most suitable existing option for assessing fatigue in patients with progressive MS, as it separates physical and mental aspects of fatigue and includes every highly endorsed concept reported by the interviewed patients. This qualitative study identified meaningful physical and mental fatigue concepts in patients with progressive MS and preliminarily supports the use of the FSIQ-RMS for this population. More research is needed to fully validate this instrument for progressive MS.
Identifiants
pubmed: 35266103
doi: 10.1007/s40120-022-00337-9
pii: 10.1007/s40120-022-00337-9
pmc: PMC8906518
doi:
Types de publication
Journal Article
Langues
eng
Pagination
725-739Informations de copyright
© 2022. The Author(s).
Références
Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8.
doi: 10.1111/j.1750-3639.2007.00064.x
Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ, International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology. 2020;94(24):1088–92.
doi: 10.1212/WNL.0000000000009636
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.
doi: 10.1212/WNL.0000000000000560
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–16.
doi: 10.1093/brain/awl007
Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314–24.
doi: 10.1177/1352458507084264
Rooney S, Wood L, Moffat F, Paul L. Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of multiple sclerosis. Mult Scler Relat Disord. 2019;28:276–82.
doi: 10.1016/j.msard.2019.01.011
Garg H, Bush S, Gappmaier E. Associations between fatigue and disability, functional mobility, depression, and quality of life in people with multiple sclerosis. Int J MS Care. 2016;18(2):71–7.
doi: 10.7224/1537-2073.2015-013
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(6):642–51.
doi: 10.1136/jnnp-2018-320050
Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18(6):26.
doi: 10.1007/s11940-016-0411-8
Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler. 1999;5(4):251–9.
doi: 10.1177/135245859900500410
Newland P, Starkweather A, Sorenson M. Central fatigue in multiple sclerosis: a review of the literature. J Spinal Cord Med. 2016;39(4):386–99.
doi: 10.1080/10790268.2016.1168587
Food and Drug Administration. Guidance for industry. Patient-reported outcomes measures: Use in medical product development to support labeling claims Washington, DC: US Department of Health and Human Services; 2009 Last Updated: March 19, 2021. Available from: https://www.fda.gov/media/77832/download .
Kantarci OH. Phases and phenotypes of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):636–54.
Brichetto G, Zaratin P. Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr Opin Neurol. 2020;33(3):295–9.
doi: 10.1097/WCO.0000000000000821
Smith K. The evolving role of people with MS in clinical research—some progress but more is needed. Mult Scler. 2017;23(12):1579–82.
doi: 10.1177/1352458517729459
Zackowski KM, Freeman J, Brichetto G, Centonze D, Dalgas U, DeLuca J, et al. Prioritizing progressive MS rehabilitation research: a call from the International Progressive MS Alliance. Mult Scler. 2021;27(7):989–1001.
doi: 10.1177/1352458521999970
Kaufmann M, Salmen A, Barin L, Puhan MA, Calabrese P, Kamm CP, et al. Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. Mult Scler Relat Disord. 2020;42: 102148.
doi: 10.1016/j.msard.2020.102148
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.
doi: 10.1212/WNL.33.11.1444
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.
doi: 10.1016/j.jval.2011.06.014
Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19(8):1087–96.
doi: 10.1007/s11136-010-9677-6
Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15(5): e0232076.
doi: 10.1371/journal.pone.0232076
Guest G, Bunce A, Johnson L. How many interviews are enough?: An experiment with data saturation and variability. Field Methods. 2006;18:59–82.
doi: 10.1177/1525822X05279903
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79–83.
doi: 10.1093/clinids/18.Supplement_1.S79
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.
doi: 10.1001/archneur.1989.00520460115022
Hudgens S, Schuler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health. 2019;22(4):453–66.
doi: 10.1016/j.jval.2018.11.007
Cella D, Lai J-S, Nowinski C, Victorson D, Peterman A, Miller D, et al. Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012;78(23):1860–7.
doi: 10.1212/WNL.0b013e318258f744
Cella D, Dineen K, Arnason B, Reder A, Webster K, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996;47(1):129–39.
doi: 10.1212/WNL.47.1.129
Penner IK, McDougall F, Brown TM, Slota C, Doward L, Julian L, et al. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020;43: 102207.
doi: 10.1016/j.msard.2020.102207